Become an investor

Disclaimer
The purpose of this webpage and subsequent document is to provide information to existing and prospective investors, and potential commercial partners, about the current status of BCAL’s research and development. It is not intended to promote the use or supply of any therapeutic goods.

Important Notice
You must read this important notice in its entirety before you attempt to access the electronic version of the Prospectus through this website. This notice does not form part of the Prospectus. You must read it before you attempt to access the electronic version of the Prospectus on this website and indicate your agreement or otherwise at the bottom of this notice.

The documents and other media on the following pages (Information) relate to an offer (Offer) of fully paid ordinary shares (Shares) in BCAL Diagnostics Limited (ACN 142 051 223) (Company).

The Offer is being made pursuant to a prospectus dated 4 June 2021 (Prospectus) which has been lodged with the Australian Securities and Investments Commission (ASIC). A copy of the Prospectus is available on this website. Neither ASIC nor ASX Limited take any responsibility for the contents of the Prospectus or for the merits of the investment to which it relates.

You should ensure that any copy of the Prospectus you view or print is completely downloaded. To the extent permitted by law, the Company is not liable for any loss incurred from accessing or downloading the Prospectus from this website, including, but not limited to, data corruption on download.

Selling Restrictions
The Prospectus does not constitute an offer or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer or invitation. No action has been taken to register or qualify the Shares the subject of the Prospectus, or the Offer, or otherwise to permit the public offering of the Shares, in any jurisdiction outside Australia. The Prospectus does not constitute an offer of Shares in any jurisdiction where, or to any person to whom, it would be unlawful to issue the Prospectus.

The distribution of the Prospectus (including an electronic copy) outside Australia may be restricted by law. If you come into possession of the Prospectus outside Australia, you should observe any such restrictions and should seek your own advice on those restrictions. Any failure to comply with such restrictions may contravene applicable securities laws.

The Information must not be released or distributed in the United States or to, or for the account or benefit of, any person in the United States, or in any jurisdiction outside of Australia where distribution may be restricted by law. The Information does not constitute an offer of Shares in the United States or to, or for the account or benefit of, any US person (as defined in Regulation S under the US Securities Act of 1933 (US Securities Act)), or to any person to whom it would not be lawful outside Australia and New Zealand. The Shares referred to in the Information have not been and will not be registered under the US Securities Act, as amended, or under the securities laws of any state or other jurisdiction of the United States. Any Shares described in, or sold pursuant to, the Information may not be offered or sold in the United States or to, or for the account or benefit of, any person in the United States absent registration under the US Securities Act or pursuant to an applicable exemption from, or a transaction not subject to, such registration, or to any person to whom it would not be lawful.

By proceeding you confirm that you have read, understood and agree to the full terms of this notice, and you represent, warrant and agree that:

1. you are a resident of Australia accessing this website from Australia;

2. you are a person who is eligible to receive the Prospectus and apply for Shares pursuant to the Offer; and

3. you are not in the United States nor are you a US person nor a person acting for the account or benefit of a US person.

Disclaimer
The purpose of this webpage and subsequent document is to provide information to existing and prospective investors, and potential commercial partners, about the current status of BCAL’s research and development. It is not intended to promote the use or supply of any therapeutic goods.

Important Notice
You must read this important notice in its entirety before you attempt to access the electronic version of the Prospectus through this website. This notice does not form part of the Prospectus. You must read it before you attempt to access the electronic version of the Prospectus on this website and indicate your agreement or otherwise at the bottom of this notice.

The documents and other media on the following pages (Information) relate to an offer (Offer) of fully paid ordinary shares (Shares) in BCAL Diagnostics Limited (ACN 142 051 223) (Company).

The Offer is being made pursuant to a prospectus dated 4 June 2021 (Prospectus) which has been lodged with the Australian Securities and Investments Commission (ASIC). A copy of the Prospectus is available on this website. Neither ASIC nor ASX Limited take any responsibility for the contents of the Prospectus or for the merits of the investment to which it relates.

You should ensure that any copy of the Prospectus you view or print is completely downloaded. To the extent permitted by law, the Company is not liable for any loss incurred from accessing or downloading the Prospectus from this website, including, but not limited to, data corruption on download.

Selling Restrictions
The Prospectus does not constitute an offer or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer or invitation. No action has been taken to register or qualify the Shares the subject of the Prospectus, or the Offer, or otherwise to permit the public offering of the Shares, in any jurisdiction outside Australia. The Prospectus does not constitute an offer of Shares in any jurisdiction where, or to any person to whom, it would be unlawful to issue the Prospectus.

The distribution of the Prospectus (including an electronic copy) outside Australia may be restricted by law. If you come into possession of the Prospectus outside Australia, you should observe any such restrictions and should seek your own advice on those restrictions. Any failure to comply with such restrictions may contravene applicable securities laws.

The Information must not be released or distributed in the United States or to, or for the account or benefit of, any person in the United States, or in any jurisdiction outside of Australia where distribution may be restricted by law. The Information does not constitute an offer of Shares in the United States or to, or for the account or benefit of, any US person (as defined in Regulation S under the US Securities Act of 1933 (US Securities Act)), or to any person to whom it would not be lawful outside Australia and New Zealand. The Shares referred to in the Information have not been and will not be registered under the US Securities Act, as amended, or under the securities laws of any state or other jurisdiction of the United States. Any Shares described in, or sold pursuant to, the Information may not be offered or sold in the United States or to, or for the account or benefit of, any person in the United States absent registration under the US Securities Act or pursuant to an applicable exemption from, or a transaction not subject to, such registration, or to any person to whom it would not be lawful.

By proceeding you confirm that you have read, understood and agree to the full terms of this notice, and you represent, warrant and agree that:

1. you are a resident of Australia accessing this website from Australia;

2. you are a person who is eligible to receive the Prospectus and apply for Shares pursuant to the Offer; and

3. you are not in the United States nor are you a US person nor a person acting for the account or benefit of a US person.